File S1 - Urinary and Plasma Levels of Vasohibin-1 Can Predict Renal Functional Deterioration in Patients with Renal Disorders

Tables S1–S9. Table S1. The clinical parameters of the study groups after three years (n = 25). Table S2. The final (after three years) characteristics of the patients with renal biopsy (n = 15). Table S3. The baseline characteristics of the patients classified by the plasma and urinary levels of vasohibin-1 and the plasma levels of the vasohibin-1-small vasohibin-binding protein complex. At baseline, the SBP was significantly lower in the group with elevated plasma levels of VASH-1 compared with the group with lower plasma levels of VASH-1. Similarly, the SBP was significantly lower in the group with elevated plasma levels of VASH-1-SVBP complex compared with lower plasma levels. The group with elevated urinary levels of VASH-1 was older and exhibited lower renal function compared with the group with lower levels at baseline. Table S4. The final (after three years) characteristics of the patients classified by the plasma and urinary levels of vasohibin-1 and the plasma levels of the vasohibin-1-small vasohibin-binding protein complex (n = 25). The group with elevated urinary levels of VASH-1 was older and exhibited lower renal function compared with the group with lower levels at the final follow-up (after three years). Table S5. The changes in the estimated glomerular filtration rate and the number of events in the patients classified by the plasma and urinary levels of vasohibin-1 and the plasma levels of the vasohibin-1-small vasohibin-binding protein complex. The group with elevated urinary levels of VASH-1 exhibited lower renal function compared with the group with lower levels at all of the follow-up examinations. Table S6. The CKD stage of the patients with or without renal biopsy. Most of the patients without renal biopsies were at CKD stage G3b to G5 at baseline. On the other hand, most of the patients who underwent renal biopsies were at CKD stage G1 to G3a at baseline. Table S7. The final (after three years) characteristics of the patients with or without renal biopsy, classified by the plasma levels of vasohibin-1 (n = 25). In the patients who underwent a renal biopsy, the group with elevated plasma levels of VASH-1 exhibited a lower SBP compared with the group with lower levels after three years. In patients who did not undergo a renal biopsy, the group with elevated plasma levels of VASH-1 exhibited lower renal function and an older age compared with the group with lower levels after three years. Table S8. The baseline characteristics of the patients with or without renal biopsy, classified by the urinary levels of vasohibin-1. In patients with or without renal biopsies, the groups with elevated urinary levels of VASH-1 were significantly older compared with the groups with lower VASH-1 levels at baseline. In patients without renal biopsies, the group with elevated urinary levels of VASH-1 exhibited significantly lower levels of proteinuria compared with the group with lower VASH-1 levels at baseline. Table S9. The changes in the estimated glomerular filtration rate and the number of events in patients with or without renal biopsy, classified by the urinary levels of vasohibin-1. No statistically significant differences were observed among the groups. (DOCX)